Our findings in this case report align with existing literature demonstrating that first-line EGFR tyrosine kinase inhibitors (TKIs), including osimertinib, almonertinib, and furmonertinib, offer durable responses in patients with EGFR-mutant NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.